Results 51 to 60 of about 313 (85)

Manogepix demonstrates potent <i>in vitro</i> activity against <i>Aspergillus, Coccidioides</i>, <i>Scopulariopsis/Microascus, Rasamsonia</i>, and <i>Purpureocillium</i> species, including strains with <i>in vitro</i> resistance to other antifungals. [PDF]

Antimicrob Agents Chemother
Wiederhold NP, Patterson HP, Sanders C, Canete-Gibas C.   +3 more
europepmc   +1 more source

Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update). [PDF]

Mycoses
Mansour MA, Wahid M, El Molla MAS, Helmy MH, Adel TM, Mostafa HN.   +5 more
europepmc   +1 more source

Comprehensive Overview of Candida auris: An Emerging Multidrug-Resistant Fungal Pathogen. [PDF]

J Microbiol Biotechnol
Kim JS, Cha H, Bahn YS.
europepmc   +1 more source

Drug Discovery and Repurposing for <i>Coccidioides</i>: A Systematic Review. [PDF]

J Fungi (Basel)
Saeger S, Lozano S, Wiederhold N, Yu JJ, Lopez-Ribot JL, Hung CY.   +5 more
europepmc   +1 more source

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin. [PDF]

J Fungi (Basel)
Espinel-Ingroff A, Wiederhold NP.
europepmc   +1 more source

Emerging antifungal resistance in Candida parapsilosis: the end of the innocence. [PDF]

NPJ Antimicrob Resist
Guinea J, Escribano P, Cadeau M, Lombardi L, Morio F.   +4 more
europepmc   +1 more source

Overcoming antifungal resistance in <i>Candida albicans via</i> RNA interference: a therapeutic perspective. [PDF]

Front Cell Infect Microbiol
Mundhe AK, Rajkumari R.
europepmc   +1 more source

Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach. [PDF]

Sci Rep
Saenz V, Lizcano-Salas AF, Le Pape P, Celis Ramírez AM.   +3 more
europepmc   +1 more source